Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INDP NASDAQ:LEXX NASDAQ:LPCN NASDAQ:ZIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDPIndaptus Therapeutics$1.82+3.4%$2.18$1.51▼$19.91$3.99M1.3765,175 shs6,497 shsLEXXLexaria Bioscience$0.62+1.7%$0.82$0.46▼$1.55$15.24M0.37191,035 shs17,254 shsLPCNLipocine$2.33+0.5%$5.01$1.81▼$12.37$19.32M0.5326,175 shs60,842 shsZIVOZIVO Bioscience$3.80+1.4%$5.57$1.11▼$19.65$15.21M0.043,890 shs2,083 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDPIndaptus Therapeutics-6.38%-17.76%-16.59%-2.76%-84.31%LEXXLexaria Bioscience-0.82%-14.97%-33.54%-11.28%-44.00%LPCNLipocine-2.11%-0.43%+5.45%-73.67%-29.27%ZIVOZIVO Bioscience0.00%-1.32%+56.25%-62.87%-76.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDPIndaptus Therapeutics$1.82+3.4%$2.18$1.51▼$19.91$3.99M1.3765,175 shs6,497 shsLEXXLexaria Bioscience$0.62+1.7%$0.82$0.46▼$1.55$15.24M0.37191,035 shs17,254 shsLPCNLipocine$2.33+0.5%$5.01$1.81▼$12.37$19.32M0.5326,175 shs60,842 shsZIVOZIVO Bioscience$3.80+1.4%$5.57$1.11▼$19.65$15.21M0.043,890 shs2,083 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDPIndaptus Therapeutics-6.38%-17.76%-16.59%-2.76%-84.31%LEXXLexaria Bioscience-0.82%-14.97%-33.54%-11.28%-44.00%LPCNLipocine-2.11%-0.43%+5.45%-73.67%-29.27%ZIVOZIVO Bioscience0.00%-1.32%+56.25%-62.87%-76.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINDPIndaptus Therapeutics 1.00SellN/AN/ALEXXLexaria Bioscience 2.00Hold$1.50143.90% UpsideLPCNLipocine 2.33Hold$15.00543.50% UpsideZIVOZIVO Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INDP, LPCN, LEXX, and ZIVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2026LEXXLexaria Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/6/2026LPCNLipocine HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/27/2026LPCNLipocine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ALEXXLexaria Bioscience$368K41.42N/AN/A$0.13 per share4.73LPCNLipocine$1.98M9.70N/AN/A$2.61 per share0.89ZIVOZIVO Bioscience$15.85K959.90N/AN/A($0.81) per share-4.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINDPIndaptus Therapeutics-$20.85M-$24.13N/AN/AN/AN/A-939.67%-293.64%N/ALEXXLexaria Bioscience-$11.90M-$0.47N/AN/AN/A-1,685.84%-206.02%-162.53%7/13/2026 (Estimated)LPCNLipocine-$9.63M-$1.88N/AN/AN/A-571.18%-66.70%-59.39%N/AZIVOZIVO Bioscience-$7.78M-$2.59N/AN/AN/AN/AN/A-2,240.92%5/13/2026 (Estimated)Latest INDP, LPCN, LEXX, and ZIVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026LPCNLipocine-$0.51-$0.54-$0.03-$0.54$0.16 million$0.12 million4/13/2026Q2 2026LEXXLexaria Bioscience-$0.0950-$0.06+$0.0350-$0.06$0.05 million$0.02 million3/17/2026Q4 2025INDPIndaptus Therapeutics-$4.36-$3.10+$1.26-$3.10N/AN/A3/10/2026Q4 2025LPCNLipocine-$0.60-$0.34+$0.26-$0.34$0.12 million$1.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/AZIVOZIVO BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINDPIndaptus TherapeuticsN/A1.511.51LEXXLexaria BioscienceN/A26.8426.84LPCNLipocineN/A9.999.99ZIVOZIVO BioscienceN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINDPIndaptus Therapeutics7.06%LEXXLexaria Bioscience13.06%LPCNLipocine9.11%ZIVOZIVO Bioscience12.83%Insider OwnershipCompanyInsider OwnershipINDPIndaptus Therapeutics23.60%LEXXLexaria Bioscience8.39%LPCNLipocine6.35%ZIVOZIVO Bioscience48.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINDPIndaptus Therapeutics62.24 million1.71 millionNot OptionableLEXXLexaria Bioscience724.79 million22.71 millionNot OptionableLPCNLipocine108.24 million7.72 millionNo DataZIVOZIVO Bioscience104.00 million2.91 millionNot OptionableINDP, LPCN, LEXX, and ZIVO HeadlinesRecent News About These CompaniesZivo Bioscience, Inc. Announces Transition to OTCID Marketplace56 minutes ago | businesswire.comZivo Bioscience Inc. WtApril 11, 2026 | barrons.comZIVO Bioscience Provides Special Letter to ShareholdersMarch 27, 2026 | businesswire.comMaxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)December 15, 2025 | theglobeandmail.comZIVO Bioscience releases letter to shareholdersSeptember 14, 2025 | wattagnet.comWZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic BusinessesSeptember 10, 2025 | businesswire.comZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in PoultryJune 20, 2025 | businesswire.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 7, 2025 | finance.yahoo.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 6, 2025 | businesswire.comZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in PoultryFebruary 6, 2025 | businesswire.comZivo Bioscience issues new shares, raises $1.5 millionJanuary 28, 2025 | msn.comTuesday's Insider Activity: Top Buys and Sells in US Stocks RevealedJanuary 1, 2025 | investing.comZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaDecember 20, 2024 | businesswire.comZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023March 18, 2024 | investorplace.comHarmony Biosciences HoldingsMarch 4, 2024 | forbes.comRegencell Bioscience Holdings Ltd RGCFebruary 1, 2024 | morningstar.comMZIVO Bioscience Announces Uplisting to OTCQB MarketJanuary 29, 2024 | finance.yahoo.comIdeaya BiosciencesJanuary 18, 2024 | forbes.comDare Bioscience Inc DAREJanuary 14, 2024 | morningstar.comMZivo Bioscience Inc (ZIVO) USD0.001November 11, 2023 | hl.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINDP, LPCN, LEXX, and ZIVO Company DescriptionsIndaptus Therapeutics NASDAQ:INDP$1.82 +0.06 (+3.41%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Lexaria Bioscience NASDAQ:LEXX$0.62 +0.01 (+1.69%) As of 11:01 AM Eastern This is a fair market value price provided by Massive. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Lipocine NASDAQ:LPCN$2.33 +0.01 (+0.47%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.ZIVO Bioscience NASDAQ:ZIVO$3.80 +0.05 (+1.38%) As of 09:36 AM EasternZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
